Welcome to Crene Biotechnology!

+86-576-88205808

Product :

TAK-285

TAK-285 871026-44-7
Size Price Stock Quantity
Get Quotation Now Add to Cart Bulk Inquiry
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
Product name:TAK-285 Purity:98% min
CAS NO:871026-44-7 Solubility:DMSO : ≥ 50 mg/mL (91.25 mM)
Molecular Formula:C26H25ClF3N5O3 Package:Package according to customer requirements.
Molecular Weight:547.957 Storage:Store at -20℃
Quality control
Remarks

TAK-285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK-285 is currently being developed by Takeda. TAK-285 was found to be well tolerate in Phase I trials. Absorption of TAK-285 was rapid after oral dosing, and plasma exposure at steady-state increased in a dose-proportional fashion for doses ranging from 50 to 300 mg b.i.d. A partial response was observed for one patient with parotid cancer who received 300 mg b.i.d. The toxicity profile and PK properties of oral TAK-285 warrant further evaluation.

 

 

 

 

HER2 Inhibitors Related Products:

Poziotinib (HM781-36B); Mubritinib; Tucatinib; Canertinib; Canertinib dihydrochloride; Lapatinib; Lapatinib ditosylate; Afatinib (BIBW2992); Afatinib (BIBW2992) Dimaleate; CUDC-101; Sapitinib

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Friendly link:

Copyright Copyright (C) 2018-2024 Taizhou Crene Biotechnology Co.,Ltd.  

Address:Economic Developed Zone of Taizhou Zhejiang China